Page last updated: 2024-12-08

1,2,3,4-tetrahydroisoquinoline carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,2,3,4-Tetrahydroisoquinoline carboxylic acid (THIQ-CA) is a **heterocyclic compound** that has attracted attention in research due to its potential therapeutic applications and its role in understanding the structure-activity relationships of various pharmaceutical compounds.

**Structure:**

THIQ-CA consists of a tetrahydroisoquinoline ring system with a carboxylic acid group attached to the aromatic ring.

**Importance in Research:**

* **Neurotransmitter Modulation:** THIQ-CA has been shown to exhibit **antidepressant-like effects** in animal models. This property is linked to its ability to modulate the activity of various neurotransmitters, including dopamine, serotonin, and norepinephrine.
* **Anti-Inflammatory Activity:** Some studies suggest that THIQ-CA may possess anti-inflammatory properties. This makes it a potential candidate for the treatment of inflammatory conditions like arthritis and inflammatory bowel disease.
* **Cancer Research:** THIQ-CA has shown some anti-cancer activity in laboratory settings. Its potential to inhibit the growth of certain cancer cells warrants further investigation.
* **Pharmacological Scaffold:** THIQ-CA's structure serves as a versatile scaffold for the development of new drugs. By modifying its chemical structure, researchers can create novel compounds with improved potency, selectivity, and pharmacokinetic properties.

**Challenges and Future Directions:**

* **Limited Clinical Data:** While preclinical studies have shown promise, clinical trials are needed to assess the safety and efficacy of THIQ-CA in humans.
* **Drug Metabolism and Pharmacokinetics:** Understanding how THIQ-CA is metabolized and distributed in the body is crucial for its development as a drug.
* **Structure-Activity Relationships:** Further exploration of the relationship between the chemical structure of THIQ-CA and its biological activity is needed to design more effective drugs.

**Overall, 1,2,3,4-tetrahydroisoquinoline carboxylic acid holds great promise for research due to its potential therapeutic applications. Further investigation is necessary to translate these preclinical findings into clinical therapies.**

1,2,3,4-tetrahydroisoquinoline carboxylic acid: RN given refers to cpd with locants as specified [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID189112
CHEMBL ID1616107
SCHEMBL ID514422
MeSH IDM0098372

Synonyms (45)

Synonym
CBMICRO_037756
BB 0255233
SDCCGMLS-0013674.P002
CHEMDIV2_002122
1,2,3,4-tetrahydro-isoquinoline-1-carboxylic acid
thiqc
41034-52-0
HMS1375A10
1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid
AKOS000601652
FT-0639689
STK675636
A6825
1,2,3,4-tetrahydroisoquinolinecarboxylic acid
FT-0643461
FT-0643462
1,2,3,4-tetrahydroisoquinoline carboxylic acid
tetrahydroisoquinoline-3-carboxylate
tetrahydroisoquinoline carboxylic acid
l-tetrahydro-3-isoquinoline carboxylic acid
1-isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-
AM20040432
AB14831
AB14827
AB08729
AKOS016344053
(+/-)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid
tetrahydroisoquinoline-1-carboxylic acid
OXFGRWIKQDSSLY-UHFFFAOYSA-N
1,2,3,4-tetrahydroisoquinolin-1-carboxylic acid
1,2,3,4-tetrahydro-1-isoquinolinecarboxylic acid
1,2,3,4-tetrahydro-1-isoquinoline carboxylic acid
SCHEMBL514422
FS-2257
mfcd01318704
mfcd03426332
SY020682
CHEMBL1616107
Q-102338
AC-29612
SY018413
CS-0005330
EN300-56240
DTXSID001347435
SY038411

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" This finally results in inhibitors, which do not only show high biological affinity for MMP-8, but also exhibit good oral bioavailability in several animal species."( Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship.
Barbier, D; Billen, G; Haase, B; Matter, H; Neises, B; Schudok, M; Schwab, W; Thorwart, W; Weithmann, K; Wollmann, T, 2002
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Moreover, CETSA melt and ITDRFCETSA (isothermal dose-response fingerprint) curves confirmed that B7 bound to Hsp90α in 293T cells."( Design and synthesis of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-1,2,3,4-tetrahydroisoquinoline-3-carboxamides as novel Hsp90 inhibitors.
Hao, H; Li, Z; Liang, C; Lu, C; Shen, Y; Wu, X; Zhu, J, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (11.11)18.7374
1990's4 (22.22)18.2507
2000's8 (44.44)29.6817
2010's3 (16.67)24.3611
2020's1 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.73 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]